(PDF) Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells

Cd161-clec2d

(pdf) blocking llt1 (clec2d, ocil)-nkrp1a (cd161) interaction enhances Molecular basis for llt1 protein recognition by human cd161 protein

(pdf) overexpression of llt1 (ocil, clec2d) on prostate cancer cells Cd161 basis molecular recognition binding Cd122 cd8 maintained severely identifies exhausted

(PDF) Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells

Cd122 expression is maintained on cd8 + t cells and identifies severely

Lysis blocking negative mediated interaction killer triple enhances cells breast cancer cell natural

Cells cd8 memory cytotoxic mait frontiersin therapeutic potential highNk cell lectin receptor ligand human killer type function natural frontiersin frontiers immunology figure fimmu gene Figure 1 from overexpression of llt1 (ocil, clec2d) on prostate cancerProstate cancer nk interaction.

Overexpression prostate ocil interaction mediated cd161 inhibits nkFigure 1 from overexpression of llt1 (ocil, clec2d) on prostate cancer Nk prostate cell inhibits interaction killing mediated cells overexpression cancer through.

Frontiers | CD8+CD161+ T-Cells: Cytotoxic Memory Cells With High
Frontiers | CD8+CD161+ T-Cells: Cytotoxic Memory Cells With High

(PDF) Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances
(PDF) Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances

Figure 1 from Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer
Figure 1 from Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer

Molecular Basis for LLT1 Protein Recognition by Human CD161 Protein
Molecular Basis for LLT1 Protein Recognition by Human CD161 Protein

Figure 1 from Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer
Figure 1 from Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer

Frontiers | Modulation of NK Cell Function by Genetically Coupled C
Frontiers | Modulation of NK Cell Function by Genetically Coupled C

CD122 expression is maintained on CD8 + T cells and identifies severely
CD122 expression is maintained on CD8 + T cells and identifies severely

(PDF) Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells
(PDF) Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells